Cargando…
Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review
BACKGROUND: Germline DNA mismatch repair (MMR) gene aberrations are associated with colorectal cancer (CRC) predisposition and high tumor mutation burden (TMB-H), with increased likelihood of favorable response to immune checkpoint inhibitors (ICIs). CASE PRESENTATION: We present a 32-year old male...
Autores principales: | Xie, Tong, Feng, Qin, Li, Zhongwu, Lu, Ming, Li, Jian, Lizaso, Analyn, Xiang, Jianxing, Zhang, Lu, Shen, Lin, Peng, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797131/ https://www.ncbi.nlm.nih.gov/pubmed/33422121 http://dx.doi.org/10.1186/s13053-021-00165-2 |
Ejemplares similares
-
Rare compound heterozygous mutations in gene MSH6 cause constitutive mismatch repair deficiency syndrome
por: Ling, Chao, et al.
Publicado: (2018) -
Exceptional Response to Pembrolizumab in a Mismatch Repair-Deficient Aggressive Prostate Cancer with Somatic EPCAM, MSH2, and MSH6 Co-Deletion: A Case Report
por: Hoch, Dennis, et al.
Publicado: (2023) -
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
por: Durno, Carol, et al.
Publicado: (2021) -
Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2–MSH6 complex
por: Banerjee, Sreeparna, et al.
Publicado: (2005) -
Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2–MSH6 complex
por: Banerjee, Sreeparna, et al.
Publicado: (2005)